Addition of capivasertib to fulvestrant doubles progression-free survival in HR-positive breast cancer patients

Science Instruments in laboratory room. Science Research Concept.

In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to fulvestrant (Faslodex) doubled the median progression-free survival compared with placebo plus fulvestrant in the phase III CAPItello-291 clinical trial, according to results presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

What Drives Choosing Flutter Over React Native?

Previous article

Edible coating made from silk can extend shelf life of foods

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News